SCHEMBL10244519

SCHEMBL10244519

COC(=O)NCCNC(C)c1cc(OC)ccc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.43
MTNR1B P49286 5/20 0.43
HPGD P15428 3/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.40
TDP2 O95551 1/20 0.40
POLB P06746 1/20 0.40
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
ACHE P22303 1/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243952 0.81 POLB (0.51) MTNR1AMTNR1BHPGDALDH1A1POLB
SCHEMBL335111 0.81 KMT2A (0.47) HPGDGAAKDM4EMEN1ALDH1A1
SCHEMBL10243936 0.78 CA12 (0.40) MEN1KMT2AMAPTCA1CA2
SCHEMBL10244860 0.77 RRM1 (0.35) MEN1ALDH1A1KMT2AMAPTADRB2
SCHEMBL10243687 0.77 CASR (0.56) MTNR1AMTNR1BMEN1KMT2AL3MBTL1
SCHEMBL10244323 0.76 SLC22A3 (0.51) GAALMNATSHR
SCHEMBL10244611 0.75 HPGD (0.49) MTNR1AMTNR1BHPGDL3MBTL1POLB
SCHEMBL10244889 0.73 CA12 (0.40) MTNR1AMTNR1BMAPTCA1CA2
SCHEMBL10244507 0.73 MAPT (0.41) HPGDKDM4EMEN1ALDH1A1KMT2A
SCHEMBL10244522 0.72 RRM1 (0.42) MTNR1AMTNR1BALDH1A1ADRB3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MTNR1A 2892/4885MTNR1B 2314/4885HPGD 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.